Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 Trial
M Hasib Sidiqi(Curtin University), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Carolyn C. Jackson(Centro de Investigación del Cáncer), Abdullah Khan(Dana-Farber Cancer Institute), Hermann Einsele(Universitätsklinikum Würzburg), Erika Florendo(Centro de Investigación del Cáncer), Jesús F. San Miguel(Clinica Universidad de Navarra), Nikoletta Lendvai(Centro de Investigación del Cáncer), Lionel Karlin(Hôpital Lyon Sud), Mythili Koneru(Cooper Medical School of Rowan University), Diana Chen, Salomon Manier(Université de Lille), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Katherine Li(Janssen (United States)), Paolo Corradini(Gruppo di Ricerca Geriatrica), Arnob Banerjee(Johnson & Johnson (United States)), Binod Dhakal(Medical College of Wisconsin), Duncan Purtill(Fiona Stanley Hospital), Jane Gilbert(Janssen (United Kingdom)), Carolina Lonardi(Janssen (Switzerland)), Ana Slaughter(Centro de Investigación del Cáncer), Tito Roccia(Janssen (United States)), Shinsuke Iida(Nagoya City University Hospital), Jordan M. Schecter(Centro de Investigación del Cáncer), Brea Lipe(University of Rochester), William Deraedt(Janssen (Belgium)), Man Zhao, Simon J. Harrison(Peter MacCallum Cancer Centre), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Octavio Costa Filho(490 BioTech (United States)), Dong Geng, Nitin Patel(Centro de Investigación del Cáncer)
Cited by 4
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k